The study is a randomized, double-blind phase 1 trial including 3 independent parts: single ascending dose(SAD) part,multiple ascending dose(MAD) part and postprandial pharmacokinetics part. SAD and MAD are dose-escalated tolerant study designed 8 cohorts and 5 cohorts in SAD and MAD respectively. The aims of the study as below:~Evaluating the safety and tolerance of Jaktinib in healthy volunteers.~Evaluating the fasting pharmacokinetic parameters of Jaktinib in healthy volunteers.~Evaluating the postprandial pharmacokinetic parameters of jaktinib in healthy volunteers.~Analysis the metabolites of Jaktinib
A randomized, double-blinding, dose-escalated phase 1 trial to evaluate the tolerance and fasting/postprandial pharmacokinetics of jaktinib.